Evidence map›Paper›PMID 27319223›Full record

ArticleJournal of biomedical nanotechnology2016

Polyanhydride Nanovaccines Induce Germinal Center B Cell Formation and Sustained Serum Antibody Responses.

Julia E Vela Ramirez, Lorraine T Tygrett, Jihua Hao, Habtom H Habte, Michael W Cho, Neil S Greenspan, Thomas J Waldschmidt, Balaji Narasimhan

Open access · greenAbstract read
In one paragraph

Article in Journal of biomedical nanotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  2. Article
  3. Polyanhydride Chemistry.Biomacromolecules · 2022
    Review
  4. Review
  5. Article
  6. Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021
    Review
  7. Review
  8. Review
  9. Article
  10. Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery.Journal of biomedical materials research. Part A · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Current state and challenges in developing oral vaccines.Advanced drug delivery reviews · 2017
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Julia E Vela Ramirez
Lorraine T Tygrett
Jihua Hao
Habtom H Habte
Michael W Cho
Neil S Greenspan
Thomas J Waldschmidt
Balaji Narasimhan
Iowa State University · USCase Western Reserve University · USUniversity of Iowa · US

Funding

Vaccine Delivery Platform DevelopmentU19AI091031 · NIAID · IOWA STATE UNIVERSITY · PI CHO, MICHAEL W · 2010 to 2013
$5.1M
NIAID NIH HHS U19 AI-091031NIAID NIH HHS U19 AI091031
6 · The paper itself

Abstract

Biodegradable polymeric nanoparticle-based subunit vaccines have shown promising characteristics by enhancing antigen presentation and inducing protective immune responses when compared with soluble protein. Specifically, polyanhydride nanoparticle-based vaccines (i.e., nanovaccines) have been shown to successfully encapsulate and release antigens, activate B and T cells, and induce both antibody- and cell-mediated immunity towards a variety of immunogens. One of the characteristics of strong thymus-dependent antibody responses is the formation of germinal centers (GC) and the generation of GC B cells, which is part of the T helper cell driven cellular response. In order to further understand the role of nanovaccines in the induction of antigen-specific immune responses, their ability to induce germinal center B cell formation and isotype switching and the effects thereof on serum antibody responses were investigated in these studies. Polyanhydride nanovaccines based on 1,6-bis(p-carboxyphenoxy)hexane and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane were used to subcutaneously administer a viral antigen. GC B cell formation and serum antibody responses induced by the nanovaccines were compared to that induced by alum-based vaccine formulations. It was demonstrated that a single dose of polyanhydride nanovaccines resulted in the formation of robust GCs and serum antibody in comparison to that induced by the alum-based formulation. This was attributed to the sustained release of antigen provided by the nanovaccines. When administered in a multiple dose regimen, the highest post-immunization titer and GC B cell number was enhanced, and the immune response induced by the nanovaccines was further sustained. These studies provide foundational information on the mechanism of action of polyanhydride nanovaccines.

Indexed as

AnimalsAntibodiesB-LymphocytesFemaleGerminal CenterMiceMice, Inbred BALB CNanoparticlesNanotechnologyPolyanhydridesT-Lymphocytes, Helper-InducerVaccines, SubunitAntibodiesPolyanhydridesVaccines, Subunit

Identifiers

PMID27319223
PMCPMC5438750
OpenAlexW2338375232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.